ESMO/LinkedIn
Jun 24, 2025, 08:52
Elene Mariamidze Highlighted Age-Related Treatment Gaps in Gynaecologic Cancer in ESMO Daily Reporter at ESMO Gynae 2025
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“In an Opinion piece in the ESMO Daily Reporter, Elene Mariamidze discusses presentations at ESMO Gynae25 that explore age-related treatment of Gynaecologic Cancer.
A registry analysis in Ovarian Cancer revealed that in patients ≥75 years, 65% received suboptimal surgical treatment and 50% received suboptimal chemotherapy. Four-year overall survival (OS) rates were only 58% for older patients versus 87% for younger patients. When older patients received optimal treatment, a 4-year OS rate of 89% was achieved, highlighting that age itself is not the limiting factor, but access to guideline-concordant care is.
Furthermore, results from the DUO-E trial showed that durvalumab, with or without olaparib, added to carboplatin/paclitaxel was effective irrespective of age in newly diagnosed advanced/recurrent Endometrial Cancer.
Read her full article here.”
More posts featuring ESMO on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 24, 2025, 15:53
Jun 24, 2025, 11:46
Jun 24, 2025, 10:32